|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Labetalol#Use in Specific Populations]] |
| {{Labetalol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| ===Pregnancy===
| |
| | |
| '''Teratogenic Effects''': Pregnancy Category C: Teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four times the maximum recommended human dose (MRHD), respectively. No reproducible evidence of fetal malformations was observed. Increased fetal resorptions were seen in both species at doses approximating the MRHD. A teratology study performed with labetalol in rabbits at IV doses up to 1.7 times the MRHD revealed no evidence of drug related harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| Nonteratogenic Effects: Hypotension, bradycardia, hypoglycemia, and respiratory depression have been reported in infants of mothers who were treated with labetalol HCl for [[hypertension]] during pregnancy. Oral administration of labetalol to rats during late gestation through weaning at doses of two to four times the MRHD caused a decrease in neonatal survival.
| |
| | |
| ===Labor & Delivery===
| |
| | |
| Labetalol HCl given to pregnant women with [[hypertension]] did not appear to affect the usual course of labor and delivery. | |
| | |
| ===Nursing Mothers===
| |
| | |
| Small amounts of labetalol (approximately 0.004% of the maternal dose) are excreted in human milk. Caution should be exercised when labetalol[[hydrochloride]] tablets are administered to a nursing woman.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.
| |
| | |
| ===Geriatric Use===
| |
| | |
| As in the general population, some elderly patients (60 years of age and older) have experienced orthostatic [[hypotension]], [[dizziness]], or lightheadedness during treatment with labetalol. Because elderly patients are generally more likely than younger patients to experience orthostatic symptoms, they should be cautioned about the possibility of such side effects during treatment with labetalol.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LABETALOL HYDROCHLORIDE INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abfc6b75-1ed5-41f1-0484-4597488237bc | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |